

Meet MAT



It's the biopharmaceutical industry's mission to find lifesaving treatments. It's also our responsibility to help patients access them.

To help provide patients with more transparency about medicine costs, PhRMA member companies created the Medicine Assistance Tool, or MAT. The platform provides patients, caregivers and health care providers with information to help them connect to financial assistance programs for the medicines patients need. MAT also links to member company websites, referenced in company direct-to-consumer television advertising, where information about the cost of the prescription medicine is available.

WHAT IS PHRMA'S MEDICINE ASSISTANCE TOOL?

The Medicine Assistance Tool (MAT) is a web platform designed to help patients, caregivers and health care providers learn more about some of the resources available to assist in accessing medicines. These include various biopharmaceutical industry programs offered to those who need financial support due to their lack of insurance or inadequate prescription medicine coverage. It also helps people learn more about the costs surrounding their medicines, as well as provides resources to help them better navigate their insurance coverage. MAT is not its own patient assistance program, but rather a search engine for many of the support programs and resources that the biopharmaceutical industry has been offering for decades.

HOW DOES MAT WORK?

MAT is a search engine that contains information on more than 900 public and private assistance programs that help patients access their prescription medicines, including some free or nearly free options. To use MAT, go to MAT.org and select whether you are a patient, loved one or health care professional. Next, enter the name of the medicines you, your loved one or your patient are prescribed and then enter your personal information or that of your loved one or patient (i.e. age, location, income, insurance coverage and household size). MAT will produce search results that identify programs and resources that might be able to help you. Any information provided is kept strictly confidential and will not be used to for any purpose other than providing the search results.

WHO IS INVOLVED IN MAT?

MAT was created by PhRMA, which represents America's top innovative biopharmaceutical research companies. There are hundreds of programs offered by PhRMA's members companies to help qualifying patients. PhRMA works in partnership on MAT with health care providers, pharmacists, patient advocacy organizations and community groups in an ongoing effort to make it easier for those with financial need to access their prescription medicines.

HOW CAN MAT HELP PATIENTS LEARN MORE ABOUT THEIR MEDICINE COSTS?

MAT provides patients, caregivers and health care providers with links to websites, referenced in company television advertising, where information about the cost of the prescription medicine is available. These websites may include information such as the list price of the medicine, out-of-pocket costs and other context about the potential costs of the medicine.


YOUR GUIDE TO USING MAT IN 3 EASY STEPS

Step 1




Visit **MAT.org** and select whether you are a patient, loved one or health care professional.

Step 2



Enter the name of the medicines you, your loved one or your patient are prescribed.

Step 3




Enter your personal information or that of your loved one or patient.

Once you follow these steps, **MAT** will produce search results that identify programs and resources that might be able to help you.

VISIT MAT.ORG TODAY.

medicine
assistance
tool.org





Novo Nordisk understands that affordability challenges are driven by a variety of factors and is committed to providing options

NNI invests heavily in access rebates and copay programs to ensure our medicines are accessible and affordable to the majority of patients, while at the same time engaging external stakeholders to drive change.

We believe it's important to understand the various affordability support programs available to patients, as out-of-pocket costs vary depending on a patient's drug coverage and benefit design.

While Novo Nordisk continues to support investments in current patient affordability offerings, we recognize additional options are necessary.



New options are now available to help more people with diabetes



My\$99Insulin

- **What:** Option to get up to three vials or two packs of pens of any combination of Novo Nordisk Inc. insulins for \$99.
- **For Who:** Eligible patients with a valid prescription. This program primarily benefits those who are uninsured; however it is available to those with insurance if they choose to go outside the system.
- **How:** By visiting [NovoCare.com](https://www.novocare.com) or calling **1.844.NOVO4ME**. Once enrolled, patients will receive an online card to be redeemed at their pharmacy. For additional details about eligibility and other restrictions please see [NovoCare.com](https://www.novocare.com).



NNPI Follow-On Brands

- **What:** Follow-on branded versions, also known as authorized generics of both a rapid acting and a premixed insulin in vials and pens are available from Novo Nordisk Pharma, Inc. (NNPI), a Novo Nordisk A/S company at a **50% discount** compared to current list price of branded versions.
- **For Who:** Anyone with a valid prescription. This may be a helpful option depending on a person's benefit design and formulary coverage, especially for those in high-deductible health plans or exposed to list price through coinsurance. This also may count towards a person's deductible.
- **How:** Patients can order these medicines from any pharmacy in the U.S. and it should be available in 1-3 business days.



Immediate Supply

- **What:** A **free** one-time, immediate supply of up to three vials or two packs of pens of Novo Nordisk Inc. insulin.
- **For Who:** Eligible patients with a valid prescription who are at risk of rationing and can't wait the time it may take for other affordability offerings to process, while exploring a longer-term solution.
- **How:** By visiting [NovoCare.com](https://www.novocare.com) or calling **1.844.NOVO4ME**. For additional details about eligibility and other restrictions please see [NovoCare.com](https://www.novocare.com).

These new options expand upon existing offerings already available



A Patient Assistance Program (PAP)

- **What:** Provides free medicines, including all Novo Nordisk Inc. insulins.
- **For Who:** Patients who are U.S. citizens or legal residents who meet certain eligibility requirements including that the total household income is at or below 400% of the federal poverty level, not having any private prescription coverage such as HMO or PPO, and not having or qualifying for other government programs, with some exceptions (Medicare patients who have spent \$1,000 on prescription drugs in the calendar year, Medicare patients who don't have Part D coverage and have been denied the federal government's Extra Help/low income subsidy, and patients who are Medicaid eligible but have been denied Medicaid).
- **How:** By visiting NovoCare.com or calling **1.844.NOVO4ME**. Please visit NovoCare.com for full eligibility details.

In 2018
~50,000
patients received
free insulin
through our PAP. In 2019,
Novo Nordisk expanded
PAP eligibility to those at
or below 400% FPL.



Novo Nordisk Human Insulin

- **What:** Human insulin available at national pharmacies like Walmart and CVS for about \$25/vial.
- **For Who:** Provides an affordable option for patients who have determined with their doctor that human insulin is an appropriate option for them, regardless of their insurance coverage status.
- **How:** By going to their local Walmart or CVS pharmacy* or visiting NovoCare.com.

~500,000
Americans
are using Novo Nordisk human
insulin through these programs.



Copay Savings Cards

- **What:** Coupons and copay cards to help defray high out-of-pocket costs.
- **For Who:** Eligible commercially insured patients who have a valid prescription.
- **How:** By visiting NovoCare.com or calling **1.844.NOVO4ME** to enroll. Eligibility and other restrictions apply. Please see NovoCare.com for details.

In 2018, Novo Nordisk provided more than
\$200 million
in assistance to patients through
coupons and copay cards.



While we will continue to do what we can, changes within the system are required to make sustainable and meaningful affordability a reality.



The U.S. Internal Revenue Service recently designated insulin as a preventive medicine. This allows HDHP-HSAs to cover insulin prior to a patient meeting their deductible, providing first dollar coverage. This change is not automatic and we encourage payers and employers to adopt this rule in order for patients to benefit.



NovoCare® is Novo Nordisk's Go-To Resource for Access and Affordability Support. NovoCare.com unifies important affordability resources for patients by creating one central destination for all Novo Nordisk Patient Support Programs. Visit NovoCare.com or call us at **1.844.NOVO4ME** (1.844.668.6463) to learn more about Novo Nordisk affordability offerings.

*More information available at ReducedRx.com

NovoCare® is a registered trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

